Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Literature DB >> 19567619

Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Bryan R Luce¹, Judith M Kramer, Steven N Goodman, Jason T Connor, Sean Tunis, Danielle Whicher, J Sanford Schwartz.

Abstract

Mesh：

Year: 2009 PMID： 19567619 DOI： 10.7326/0003-4819-151-3-200908040-00126

Source DB: PubMed Journal: Ann Intern Med ISSN： 0003-4819 Impact factor: 25.391

Keyword Cloud
Cited

× No keyword cloud information.

106 in total

1. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry.

Authors: Robert W Yeh; Matthew J Czarny; Sharon-Lise T Normand; Dean J Kereiakes; David R Holmes; Ralph G Brindis; W Douglas Weaver; John S Rumsfeld; Matthew T Roe; Sunghee Kim; Priscilla Driscoll-Shempp; Laura Mauri
Journal: Circ Cardiovasc Qual Outcomes Date: 2014-11-16

2. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Authors: Adam M Huber; Angela B Robinson; Ann M Reed; Leslie Abramson; Sharon Bout-Tabaku; Ruy Carrasco; Megan Curran; Brian M Feldman; Harry Gewanter; Thomas Griffin; Kathleen Haines; Mark F Hoeltzel; Josephine Isgro; Philip Kahn; Bianca Lang; Patti Lawler; Bracha Shaham; Heinrike Schmeling; Rosie Scuccimarri; Michael Shishov; Elizabeth Stringer; Julie Wohrley; Norman T Ilowite; Carol Wallace
Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794

3. Evaluating large-scale health programmes at a district level in resource-limited countries.

Authors: Theodore Svoronos; Kedar S Mate
Journal: Bull World Health Organ Date: 2011-08-23 Impact factor: 9.408

4. Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective.

Authors: Ralph M Meyer; Heather A Stanton; Wendy R Parulekar; Fred Saad
Journal: Can Urol Assoc J Date: 2011-12 Impact factor: 1.862

5. A new taxonomy for stakeholder engagement in patient-centered outcomes research.

Authors: Thomas W Concannon; Paul Meissner; Jo Anne Grunbaum; Newell McElwee; Jeanne-Marie Guise; John Santa; Patrick H Conway; Denise Daudelin; Elaine H Morrato; Laurel K Leslie
Journal: J Gen Intern Med Date: 2012-04-13 Impact factor: 5.128

6. Be sure to read the fine print: the agency for healthcare research and quality comparative effectiveness report on antiepileptic drugs.

Authors: Timothy E Welty; Edward Faught; Dieter Schmidt; James W McAuley; Melody Ryan
Journal: Epilepsy Curr Date: 2012-05 Impact factor: 7.500

Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

1. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry.

2. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

3. Evaluating large-scale health programmes at a district level in resource-limited countries.

4. Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective.

5. A new taxonomy for stakeholder engagement in patient-centered outcomes research.

6. Be sure to read the fine print: the agency for healthcare research and quality comparative effectiveness report on antiepileptic drugs.

7. Pharmacotherapy: How well can we compare different biologic agents for RA?

Review 8. Secondary HIV prevention: novel intervention approaches to impact populations most at risk.

9. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

10. Secondary prevention: the ongoing challenge.